Skip to Content

Ravulizumab Disease Interactions

There are 3 disease interactions with ravulizumab:


Ravulizumab (applies to ravulizumab) meningitis

Major Potential Hazard, Moderate plausibility. Applicable conditions: CNS Infection

Ravulizumab is contraindicated in patients with unresolved Neisseria meningitidis infection. Life-threatening meningococcal infections have occurred in patients treated with ravulizumab, and the drug has shown to increases patient's susceptibility to serious meningococcal infections (septicemia and/or meningitis). Patients that will receive treatment should be vaccinated for meningococcal disease according to the most current Advisory Committee on Immunization Practices (ACIP) recommendations for patients with complement deficiencies, and revaccinated in accordance with ACIP recommendations considering the duration of ravulizumab therapy. Immunize patients without a history of meningococcal vaccination at least 2 weeks prior to receiving the first dose of ravulizumab. If urgent ravulizumab therapy is indicated in an unvaccinated patient, meningococcal vaccine(s) should be administered as soon as possible with 2 weeks of antibacterial drug prophylaxis. Patients receiving ravulizumab, should be closely monitored for early signs and symptoms of meningococcal infection and if infection is suspected patients need immediate evaluation.


Ravulizumab (applies to ravulizumab) infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Ravulizumab blocks terminal complement activation; therefore, patients may have increased susceptibility to encapsulated bacteria infections, especially infections caused by Neisseria meningitidis but also Streptococcus pneumoniae, Haemophilus influenzae, and to a lesser extent, Neisseria gonorrhoeae. If ravulizumab therapy is administered to patients with active systemic infections, monitor closely for signs and symptoms of worsening infection.


Ravulizumab (applies to ravulizumab) severe renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The effect of severe renal impairment (eGFR 15 to 29 mL/min/1.73 m2) on ravulizumab pharmacokinetics is unknown.

Ravulizumab drug interactions

There are 4 drug interactions with ravulizumab

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.